Company intelligence / Profile preview

PharmAkea Therapeutics

San Diego, California, United Statespharmacompass.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PharmAkea Therapeutics developed small molecule inhibitors targeting key proteins involved in fibrotic diseases and cancer. Its lead asset, PAT‑1251 (a LOXL2 inhibitor), reached Phase II readiness for fibrotic disease and some cancers. Another program targeting autotaxin (PAT‑409) reached Phase I readiness before being sold to Blade Therapeutics. The company merged with Galecto in January 2020; the combined entity continues development under the Galecto name.

Therapeutic areas: PulmonologyOncologyGastroenterology
Modalities: Small molecules
Industry: Biotech

Partnerships

Celgene

Beyond the preview

Go deeper on PharmAkea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmAkea Therapeutics.

Explore the full profile